Indo Us Bio-Tech Limited INDOUS NSEINFRA
Company Overview
Indo Us Bio-Tech Limited engages in the production, processing, packing, and marketing of seeds in India. The company offers vegetable seeds, such as tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, pepper, chilly, sweet pepper, beet root, cow pea, corriander, onion, watermelon, musk melon, and flower seeds; cotton seeds; and oil seeds, including castor, groundnut, sesamum, mustard, and soyabean seeds. It also provides cumin and isabgul spices seeds; pulses seeds comprising val, gram, black gram, and green gram seeds; and cereals seeds consisting of wheat, maize, bajra, and pegeon pea seeds. It also exports its products. The company was incorporated in 2004 and is based in Ahmedabad, India.
Why Investors Should Care
Return on capital employed stands at 17.3%.
Net profit has compounded at 21.9% per year over the last five years.
Revenue has grown at a 21.4% CAGR over the past five years.
Trades at a P/E of 11.8, below the sector median of 27.4.
Recent Developments
- Mar 2026 Revenue of ₹110.44 Cr (+6.4% YoY); net profit ₹13.12 Cr.
- Trailing 12 Months Year-on-year growth — revenue +6.4%, earnings -19.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 21.4%, profit CAGR 21.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 21.39% |
| 1 Year: | 6.36% |
Compounded Profit Growth
| 5 Years: | 21.92% |
| 1 Year: | -19.33% |
Stock Price Performance
| 1 Year: | -54.11% |
| 6 Months: | -43.90% |
| 3 Months: | -18.94% |
| 1 Month: | -3.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.64 · Neutral
P/E of 11.85 is below the sector median of 27.43 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 21.4% over 5 years.
- Profit CAGR of 21.9% over 5 years.
CONS
- Trading 54.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INDOUS Indo Us Bio-Tech Limited NSEINFRA | 77.48 | 11.85 | ₹155.36 Cr | 0.00% | 17.27% | 14.18% | 21.39% | 21.92% |
| 2 | ULTRACEMCO UltraTech Cement Limited NIFTY50NSEINFRA | 11,408.00 | 41.12 | ₹3.36 L Cr | 1.99% | 11.84% | 10.66% | 11.92% | 17.26% |
| 3 | JSWSTEEL JSW Steel Limited NIFTY50NSEAIINFRA | 1,325.00 | 14.52 | ₹3.24 L Cr | 0.54% | 18.75% | 22.30% | 3.61% | 75.28% |
| 4 | HINDZINC Hindustan Zinc Limited NSEINFRA | 601.00 | 18.36 | ₹2.54 L Cr | 3.56% | 61.97% | 61.13% | 5.61% | 9.58% |
| 5 | ASIANPAINT Asian Paints Limited NIFTY50NSEINFRA | 2,527.30 | 56.03 | ₹2.42 L Cr | 1.00% | 24.41% | 20.24% | 1.10% | 1.75% |
| 6 | TATASTEEL Tata Steel Limited NIFTY50NSEAIINFRA | 188.79 | 21.83 | ₹2.36 L Cr | 2.11% | 11.32% | 10.56% | -1.59% | 7.21% |
| 7 | HINDALCO Hindalco Industries Limited NIFTY50NSEAIINFRA | 1,011.00 | 16.79 | ₹2.27 L Cr | 0.49% | 9.42% | 9.80% | 7.10% | 9.87% |
| 8 | GRASIM Grasim Industries Limited NIFTY50NSEINFRA | 3,322.00 | 59.86 | ₹2.26 L Cr | 0.31% | 3.98% | 4.80% | 14.30% | -10.06% |
| 9 | SOLARINDS Solar Industries India Limited NSEINFRA | 21,445.00 | 115.68 | ₹1.94 L Cr | 0.06% | 29.51% | 26.72% | 12.39% | 30.36% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 22.80 Cr | 30.77 Cr | 30.85 Cr | 22.80 Cr | 26.02 Cr |
| Cost of Revenue | 15.98 Cr | 22.12 Cr | 23.75 Cr | 15.98 Cr | 18.42 Cr |
| Gross Profit | 6.82 Cr | 8.65 Cr | 7.10 Cr | 6.82 Cr | 7.61 Cr |
| Operating Expenses | 2.89 Cr | 3.38 Cr | 3.14 Cr | 2.89 Cr | 4.65 Cr |
| Operating Income | 3.93 Cr | 5.27 Cr | 3.96 Cr | 3.93 Cr | 2.96 Cr |
| EBITDA | 4.16 Cr | 5.47 Cr | 4.19 Cr | 4.16 Cr | 3.25 Cr |
| Interest Expense | 76.73 L | 45.10 L | 42.31 L | 76.73 L | 60.19 L |
| Pretax Income | 3.16 Cr | 4.82 Cr | 3.56 Cr | 3.16 Cr | 2.38 Cr |
| Tax Provision | 16.66 L | 11.75 L | 10.68 L | 16.66 L | 40.65 L |
| Net Income | 3.00 Cr | 4.70 Cr | 3.45 Cr | 3.00 Cr | 1.97 Cr |
| Diluted EPS | 1.49 | 2.35 | 1.72 | 1.49 | 0.98 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 39.76 Cr | 39.39 Cr | - | 61.74 Cr | 72.84 Cr | 103.84 Cr | 110.44 Cr |
| Cost of Revenue | - | - | - | 45.74 Cr | 52.20 Cr | 72.66 Cr | 80.27 Cr |
| Gross Profit | - | - | - | 16.00 Cr | 20.64 Cr | 31.18 Cr | 30.17 Cr |
| Operating Expenses | 35.78 Cr | 34.04 Cr | - | 7.42 Cr | 10.28 Cr | 13.34 Cr | 14.06 Cr |
| Operating Income | 3.75 Cr | 5.08 Cr | - | 8.59 Cr | 10.36 Cr | 17.84 Cr | 16.11 Cr |
| EBITDA | 3.98 Cr | 5.35 Cr | - | 9.34 Cr | 11.00 Cr | 19.12 Cr | 17.07 Cr |
| Interest Expense | 88.00 L | 1.18 Cr | - | 1.12 Cr | 1.41 Cr | 1.49 Cr | 2.24 Cr |
| Pretax Income | 2.86 Cr | 3.93 Cr | - | 7.39 Cr | 8.79 Cr | 16.53 Cr | 13.92 Cr |
| Tax Provision | 33.00 L | -96.99 L | - | 14.65 L | 55.30 L | 26.31 L | 79.73 L |
| Net Income | 2.53 Cr | 4.90 Cr | - | 7.24 Cr | 8.24 Cr | 16.27 Cr | 13.12 Cr |
| Diluted EPS | 1.74 | 3.38 | - | 3.75 | 4.11 | 8.11 | 6.54 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 34.70 Cr | 43.71 Cr | - | 69.47 Cr | 84.46 Cr | 97.84 Cr | 133.10 Cr |
| Current Assets | - | - | - | 59.91 Cr | 73.09 Cr | 86.73 Cr | 120.69 Cr |
| Cash & Equivalents | - | - | - | 18.95 L | 1.10 Cr | 24.76 L | 6.12 Cr |
| Inventory | - | - | - | 26.91 Cr | 51.74 Cr | 70.69 Cr | 99.95 Cr |
| Receivables | - | - | - | 24.74 Cr | 19.05 Cr | 15.00 Cr | 13.76 Cr |
| Total Liabilities | - | - | - | 14.97 Cr | 21.71 Cr | 19.32 Cr | 40.56 Cr |
| Current Liabilities | - | - | - | 12.29 Cr | 18.86 Cr | 16.34 Cr | 39.52 Cr |
| Long Term Debt | - | - | - | 1.70 Cr | 2.80 Cr | 2.93 Cr | 95.19 L |
| Total Debt | 8.58 Cr | 11.57 Cr | - | 11.60 Cr | 14.32 Cr | 14.84 Cr | 37.04 Cr |
| Total Equity | 16.44 Cr | 21.34 Cr | - | 54.50 Cr | 62.75 Cr | 78.52 Cr | 92.53 Cr |
| Shares Outstanding | - | - | - | 2.01 Cr | 2.01 Cr | 2.01 Cr | 2.01 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -84.00 L | 16.00 L | - | 52.57 L | 2.22 Cr | 1.42 Cr | -12.58 Cr |
| Investing Cash Flow | -57.00 L | -1.78 Cr | - | -6.67 Cr | -2.53 Cr | -79.24 L | -1.50 Cr |
| Financing Cash Flow | 1.53 Cr | 1.55 Cr | - | 6.29 Cr | 1.22 Cr | -1.48 Cr | 19.96 Cr |
| Capital Expenditure | -37.00 L | -1.94 Cr | - | -1.82 Cr | -2.61 Cr | -86.21 L | -2.41 Cr |
| Free Cash Flow | -1.21 Cr | -1.78 Cr | - | -1.30 Cr | -38.88 L | 55.72 L | -14.99 Cr |
| Net Change in Cash | 12.00 L | -7.00 L | - | 14.12 L | 90.89 L | -85.06 L | 5.88 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 25.9% | 28.3% | 30.0% | 27.3% |
| Operating Margin % | 9.4% | 12.9% | - | 13.9% | 14.2% | 17.2% | 14.6% |
| Net Margin % | 6.4% | 12.4% | - | 11.7% | 11.3% | 15.7% | 11.9% |
| ROE % | 15.4% | 23.0% | - | 13.3% | 13.1% | 20.7% | 14.2% |
| ROCE % | - | - | - | 15.0% | 15.8% | 21.9% | 17.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INDOUS
Indo US Bio-Tech Share Price News: Market Cap, Valuation - Univest
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPdU80NVRiSGJ2RTY5c0pfVGlTTWtvdExoanpsOEo4S3NCUlNSdEVnV3RhNXItVThKaVRHckkzQWtCRVNjcWJCS05ZcEl6YkJKYkI2QmhONHE0aTJGR2gtVE1hMTFVLW5uMnNwVnlTYzRJeFhhRDh0Y2dmaFpnVGRlR1NqWQ?oc=5" targe…
Indo US Bio-Tech Ltd. Peer Comparison – Compare with Others - Value Research
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOU1JyQTVxNUNpOWMtSHNxc2tIQmtjUzZRLUowSVpBTW1tcTQybEllR2VtUzg0aUw0MndwRVBVWHBnUE5tWjRoUDJyenE0NWFnOWFxcXJvbFVIWFJ2NlNSZHZHZGJPZVN6SDZCY2lXbThhZXJ5bUhJWHNId3I3ZmtNYUg0SGpkMEtGOWdyaH…
Indo (INDOUS.NS) Results at a Glance: The Latest Report Adds New Financial Reference Points in the Latest Session; Investor Response: The Stock Records a 2.65% Increase at the Close - Revenue Recognition Risk - siam.in
<a href="https://news.google.com/rss/articles/CBMivAJBVV95cUxQeXp2a2x3M0hEYmZPNUx4TGZrTWI0OXY1ZmRUb1J6SkplTmlWQW5rQllhSG05eHI2dU9NMm9WLTZzRmVLdlRlWTZZY1NQTEM2eG9wRHRmU2ZuQ2l2aFM2QnVkQ3RuaHAxcUx5eGx5UjFpUkxhd01XZ2NoZFh4d1VsQkN0N0E4aXVVdDNwX1…
Indo Us Biotech Limited (INDOUS.NS): Consolidation Near Key Support Amid Modest Loss - Swing Entry Signals - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOMjllOTNQZEdKV0dDbkNSOVlvalpNalo4WmZ3VTRCM1ZkOVRDN2FmcW9feEV2M2NJbVo1eXVTOURGUHc1Ty05cUZyZ0RidGFQRG1zU1RFUi1yUGRkTzcyYmZ1OUNOZjBrYkF1Rll6c09sc25KOUE0R1hoU3JDRUF3dWllSWpkYU9fcTZSMm…
Indo US Bio-Tech net profit falls 35% in Q1FY27 to ₹3.04 crore - scanx.trade
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOMUJST2ZpNk4wUUozbnA2QVIzY1BkWjF1clk1YTJXX0Z1SWlQbkZGM3EyWGxHaktrX3Jjek5MRVZsWWpheG5lNHpSTmVVMDh3aXhfX296eU5Ob1AyU2xfcWhVS1gyRmZWY0xfd3BKRGlUQ3RoY2xRaHdOd1JrQm9CcVBtMm9GaXByeC1rWT…
Indo (INDOUS.NS) Price: Records a 0.37% Increase to ₹86.28 in the Latest Session; Price Levels: the Near-Term Reference Band Stretches From ₹81.97 to ₹90.59 under the Current Snapshot - MACD Signal Stocks - siam.in
<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxQYVYyWmRFLVFDOHVKX2ppY2VQOC1PNUlxUnRwNG1MR01DYUNqcWZXYjhMSFZBdkY1ZHRsNExZYmh0MlM5ME82dWhsbl9mTVVZZWYtOHc4QjBLa0hBLVRhUU50U0c4MHp4SG9HV1J0NHJZczA4YXgyWTUyUmJxMGFkUXJ0U0hlVkZEeDMtLX…
INDOUS — Frequently Asked Questions
What is the current share price of Indo Us Bio-Tech Limited (INDOUS)?
As of 2026-09-08 04:53 IST, Indo Us Bio-Tech Limited (INDOUS) trades at ₹77.48 on NSE. Its 52-week range is ₹77.48 to ₹168.85.
What is the market capitalisation of INDOUS?
Indo Us Bio-Tech Limited (INDOUS) has a market capitalisation of ₹155.36 Cr on NSE.
What is the P/E ratio of INDOUS?
INDOUS trades at a trailing price-to-earnings (P/E) ratio of 11.85. The industry average P/E is 27.43. Its price-to-book (P/B) ratio is 1.78.
What is the return on equity (ROE) of INDOUS?
INDOUS has a return on equity (ROE) of 14.18%. Its return on capital employed (ROCE) is 17.27%.
Is INDOUS a good stock to buy?
This page provides a data-driven analysis of Indo Us Bio-Tech Limited (INDOUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.